Antithrombotic regimens for percutaneous coronary intervention of the left main coronary artery: The EXCEL trial.
Sorin J BrenerNicholas J LemboDavid E KandzariManel SabatéAnthony H GershlickAdrian P BanningPaweł E BuszmanIoanna KosmidouCharles A SimontonMarie-Claude MoriceOri Ben-YehudaOvidiu DresslerZixuan ZhangJoseph F SabikArie Pieter KappeteinPatrick W SerruysGregg W StonePublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
Among patients undergoing LMCA PCI in the EXCEL trial, procedural use of bivalirudin was associated with greater rates of periprocedural MI and the 30-day composite endpoint without reducing bleeding complications. Five-year outcomes were similar. GPIs were used infrequently and were not associated with clinical outcomes.
Keyphrases
- percutaneous coronary intervention
- atrial fibrillation
- st segment elevation myocardial infarction
- coronary artery
- acute myocardial infarction
- st elevation myocardial infarction
- acute coronary syndrome
- coronary artery disease
- antiplatelet therapy
- coronary artery bypass grafting
- patients undergoing
- phase iii
- study protocol
- phase ii
- clinical trial
- pulmonary artery
- coronary artery bypass
- direct oral anticoagulants
- randomized controlled trial
- risk factors
- open label
- metabolic syndrome
- pulmonary hypertension
- venous thromboembolism